Chronic therapy with α1A-adrenergic agonist reverses RV failure and mitochondrial dysfunction

Read full text Summarise with VIRAT
Authors: On Yeung Li, Philip M. Swigart, N Reddy, Bat‐Erdene Myagmar, Enkhjin Bat-Erdene, Paul C. Simpson, Anthony J. Baker
Cited by: 0
References: 40

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT Right ventricular failure (RVF) is a serious disease with a high mortality but no effective pharmacologic treatments. We reported RVF was reversed by chronic treatment with an α1A-adrenergic receptor (α1A-AR) agonist. Recent studies suggest mitochondrial dysfunction contributes to RVF. Therefore, we investigated if reversal of RVF by chronic α1A-AR agonist treatment involved improved mitochondrial function. A mouse model of RVF caused by pulmonary artery constriction (PAC) for 2 wk was chronically treated for a further 2 wk. with a low dose of the α1A-AR agonist A61603 (10 ng/kg/day) or vehicle (no drug control). RV dysfunction was assessed from the fractional shortening of the RV outflow tract (RVOT FS). RVOT FS for sham controls (46.5 ± 1.3 %, n = 9) was reduced 4 wk after PAC (27.6 ± 1.5 %, n = 13, P < 0.0001), but was higher after PAC plus 2 wk A61603 treatment (34.5 ± 0.6 %, n = 14, P < 0.001). RV myocardial respiration rate (O 2 consumption) for sham controls (776 ± 51 pM/s/mg, n = 9) was reduced 4 wk after PAC (493 ± 28 pM/s/mg, n = 15, P

Fields of Study & Subjects

Pulmonary Hypertension Research and Treatments Cardiovascular Function and Risk Factors Mitochondrial Function and Pathology

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
20 March 2026
Language
EN
Document type
Preprint